Trial · NCT04277936
Pharmacologic Modulation of Hippocampal Activity in Psychosis
NCT04277936, Phase 2, Terminated, Vanderbilt University Medical Center; results first posted 2021-08-05
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pharmacologic Modulation of Hippocampal Activity in Psychosis. Trials, record NCT04277936. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04277936
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pharmacologic Modulation of Hippocampal Activity in Psychosis
- NCT number
- NCT04277936
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 1 participants, actual
- Lead sponsor
- Vanderbilt University Medical Center
- Conditions
- Schizophrenia; Psychosis
- Interventions
- Levetiracetam 500 mg
- First posted
- 2020-02-20
- Last updated
- 2021-08-05
- Results first posted
- 2021-08-05
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Hippocampal Activity (Arterial Spin Labeling [ASL] Study) | 2 hours and 2 weeks after administration | Change in ASL signal after drug administration |
| Primary | Hippocampal Recruitment (BOLD Study) | 2 hours and 2 weeks after administration | Change in BOLD signal after drug administration |
| Secondary | Cognitive Symptoms | 2 weeks after administration | Change in eye-tracking relational memory task |
| Secondary | Positive and Negative Symptoms | 2 weeks after administration | Change PANSS score |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Hippocampal Activity (Arterial Spin Labeling [ASL] Study) | 2 hours and 2 weeks after administration | Data were collected for a single subject, but study design was changed and study was discontinued. | ||
| PRIMARY | Hippocampal Recruitment (BOLD Study) | 2 hours and 2 weeks after administration | Data were collected for a single subject, but study design was changed and study was discontinued. | ||
| SECONDARY | Cognitive Symptoms | 2 weeks after administration | No data were collected. | ||
| SECONDARY | Positive and Negative Symptoms | 2 weeks after administration | Healthy participant; outcome measure does not apply |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Levetiracetam (LEV) 500 mg | 1 | |
| Overall Study | COMPLETED | Levetiracetam (LEV) 500 mg | 1 | |
| Overall Study | NOT COMPLETED | Levetiracetam (LEV) 500 mg | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Levetiracetam (LEV) 500 mg | 0 | 1 |
| Total, other adverse events | Levetiracetam (LEV) 500 mg | 0 | 1 |
| Total, serious adverse events | Levetiracetam (LEV) 500 mg | 0 | 1 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04277936
GET https://conductscience.org/api/trials/v1/NCT04277936/registered